Optimized inhibitors of soluble epoxide hydrolase improve in vitro target residence time and in vivo efficacy

Kin Sing Stephen Lee, Jun Yan Liu, Karen M. Wagner, Svetlana Pakhomova, Hua Dong, Christophe Morisseau, Samuel H. Fu, Jun Yang, Peng Wang, Arzu Ulu, Christina A. Mate, Long V. Nguyen, Sung Hee Hwang, Matthew L. Edin, Alexandria A. Mara, Heike Wulff, Marcia E. Newcomer, Darryl C. Zeldin, Bruce D. Hammock

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

Diabetes is affecting the life of millions of people. A large proportion of diabetic patients suffer from severe complications such as neuropathic pain, and current treatments for these complications have deleterious side effects. Thus, alternate therapeutic strategies are needed. Recently, the elevation of epoxy-fatty acids through inhibition of soluble epoxide hydrolase (sEH) was shown to reduce diabetic neuropathic pain in rodents. In this report, we describe a series of newly synthesized sEH inhibitors with at least 5-fold higher potency and doubled residence time inside both the human and rodent sEH enzyme than previously reported inhibitors. These inhibitors also have better physical properties and optimized pharmacokinetic profiles. The optimized inhibitor selected from this new series displayed improved efficacy of almost 10-fold in relieving pain perception in diabetic neuropathic rats as compared to the approved drug, gabapentin, and previously published sEH inhibitors. Therefore, these new sEH inhibitors could be an attractive alternative to treat diabetic neuropathy in humans.

Original languageEnglish (US)
Pages (from-to)7016-7030
Number of pages15
JournalJournal of Medicinal Chemistry
Volume57
Issue number16
DOIs
StatePublished - 2014

Fingerprint

Epoxide Hydrolases
Neuralgia
Rodentia
Pain Perception
Diabetic Neuropathies
Fatty Acids
Pharmacokinetics
In Vitro Techniques
Enzymes
Therapeutics
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Molecular Medicine
  • Drug Discovery

Cite this

Lee, K. S. S., Liu, J. Y., Wagner, K. M., Pakhomova, S., Dong, H., Morisseau, C., ... Hammock, B. D. (2014). Optimized inhibitors of soluble epoxide hydrolase improve in vitro target residence time and in vivo efficacy. Journal of Medicinal Chemistry, 57(16), 7016-7030. https://doi.org/10.1021/jm500694p

Optimized inhibitors of soluble epoxide hydrolase improve in vitro target residence time and in vivo efficacy. / Lee, Kin Sing Stephen; Liu, Jun Yan; Wagner, Karen M.; Pakhomova, Svetlana; Dong, Hua; Morisseau, Christophe; Fu, Samuel H.; Yang, Jun; Wang, Peng; Ulu, Arzu; Mate, Christina A.; Nguyen, Long V.; Hwang, Sung Hee; Edin, Matthew L.; Mara, Alexandria A.; Wulff, Heike; Newcomer, Marcia E.; Zeldin, Darryl C.; Hammock, Bruce D.

In: Journal of Medicinal Chemistry, Vol. 57, No. 16, 2014, p. 7016-7030.

Research output: Contribution to journalArticle

Lee, KSS, Liu, JY, Wagner, KM, Pakhomova, S, Dong, H, Morisseau, C, Fu, SH, Yang, J, Wang, P, Ulu, A, Mate, CA, Nguyen, LV, Hwang, SH, Edin, ML, Mara, AA, Wulff, H, Newcomer, ME, Zeldin, DC & Hammock, BD 2014, 'Optimized inhibitors of soluble epoxide hydrolase improve in vitro target residence time and in vivo efficacy', Journal of Medicinal Chemistry, vol. 57, no. 16, pp. 7016-7030. https://doi.org/10.1021/jm500694p
Lee, Kin Sing Stephen ; Liu, Jun Yan ; Wagner, Karen M. ; Pakhomova, Svetlana ; Dong, Hua ; Morisseau, Christophe ; Fu, Samuel H. ; Yang, Jun ; Wang, Peng ; Ulu, Arzu ; Mate, Christina A. ; Nguyen, Long V. ; Hwang, Sung Hee ; Edin, Matthew L. ; Mara, Alexandria A. ; Wulff, Heike ; Newcomer, Marcia E. ; Zeldin, Darryl C. ; Hammock, Bruce D. / Optimized inhibitors of soluble epoxide hydrolase improve in vitro target residence time and in vivo efficacy. In: Journal of Medicinal Chemistry. 2014 ; Vol. 57, No. 16. pp. 7016-7030.
@article{2f406faaf96f4a35ae7aa16e913764b7,
title = "Optimized inhibitors of soluble epoxide hydrolase improve in vitro target residence time and in vivo efficacy",
abstract = "Diabetes is affecting the life of millions of people. A large proportion of diabetic patients suffer from severe complications such as neuropathic pain, and current treatments for these complications have deleterious side effects. Thus, alternate therapeutic strategies are needed. Recently, the elevation of epoxy-fatty acids through inhibition of soluble epoxide hydrolase (sEH) was shown to reduce diabetic neuropathic pain in rodents. In this report, we describe a series of newly synthesized sEH inhibitors with at least 5-fold higher potency and doubled residence time inside both the human and rodent sEH enzyme than previously reported inhibitors. These inhibitors also have better physical properties and optimized pharmacokinetic profiles. The optimized inhibitor selected from this new series displayed improved efficacy of almost 10-fold in relieving pain perception in diabetic neuropathic rats as compared to the approved drug, gabapentin, and previously published sEH inhibitors. Therefore, these new sEH inhibitors could be an attractive alternative to treat diabetic neuropathy in humans.",
author = "Lee, {Kin Sing Stephen} and Liu, {Jun Yan} and Wagner, {Karen M.} and Svetlana Pakhomova and Hua Dong and Christophe Morisseau and Fu, {Samuel H.} and Jun Yang and Peng Wang and Arzu Ulu and Mate, {Christina A.} and Nguyen, {Long V.} and Hwang, {Sung Hee} and Edin, {Matthew L.} and Mara, {Alexandria A.} and Heike Wulff and Newcomer, {Marcia E.} and Zeldin, {Darryl C.} and Hammock, {Bruce D.}",
year = "2014",
doi = "10.1021/jm500694p",
language = "English (US)",
volume = "57",
pages = "7016--7030",
journal = "Journal of Medicinal Chemistry",
issn = "0022-2623",
publisher = "American Chemical Society",
number = "16",

}

TY - JOUR

T1 - Optimized inhibitors of soluble epoxide hydrolase improve in vitro target residence time and in vivo efficacy

AU - Lee, Kin Sing Stephen

AU - Liu, Jun Yan

AU - Wagner, Karen M.

AU - Pakhomova, Svetlana

AU - Dong, Hua

AU - Morisseau, Christophe

AU - Fu, Samuel H.

AU - Yang, Jun

AU - Wang, Peng

AU - Ulu, Arzu

AU - Mate, Christina A.

AU - Nguyen, Long V.

AU - Hwang, Sung Hee

AU - Edin, Matthew L.

AU - Mara, Alexandria A.

AU - Wulff, Heike

AU - Newcomer, Marcia E.

AU - Zeldin, Darryl C.

AU - Hammock, Bruce D.

PY - 2014

Y1 - 2014

N2 - Diabetes is affecting the life of millions of people. A large proportion of diabetic patients suffer from severe complications such as neuropathic pain, and current treatments for these complications have deleterious side effects. Thus, alternate therapeutic strategies are needed. Recently, the elevation of epoxy-fatty acids through inhibition of soluble epoxide hydrolase (sEH) was shown to reduce diabetic neuropathic pain in rodents. In this report, we describe a series of newly synthesized sEH inhibitors with at least 5-fold higher potency and doubled residence time inside both the human and rodent sEH enzyme than previously reported inhibitors. These inhibitors also have better physical properties and optimized pharmacokinetic profiles. The optimized inhibitor selected from this new series displayed improved efficacy of almost 10-fold in relieving pain perception in diabetic neuropathic rats as compared to the approved drug, gabapentin, and previously published sEH inhibitors. Therefore, these new sEH inhibitors could be an attractive alternative to treat diabetic neuropathy in humans.

AB - Diabetes is affecting the life of millions of people. A large proportion of diabetic patients suffer from severe complications such as neuropathic pain, and current treatments for these complications have deleterious side effects. Thus, alternate therapeutic strategies are needed. Recently, the elevation of epoxy-fatty acids through inhibition of soluble epoxide hydrolase (sEH) was shown to reduce diabetic neuropathic pain in rodents. In this report, we describe a series of newly synthesized sEH inhibitors with at least 5-fold higher potency and doubled residence time inside both the human and rodent sEH enzyme than previously reported inhibitors. These inhibitors also have better physical properties and optimized pharmacokinetic profiles. The optimized inhibitor selected from this new series displayed improved efficacy of almost 10-fold in relieving pain perception in diabetic neuropathic rats as compared to the approved drug, gabapentin, and previously published sEH inhibitors. Therefore, these new sEH inhibitors could be an attractive alternative to treat diabetic neuropathy in humans.

UR - http://www.scopus.com/inward/record.url?scp=84906862150&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84906862150&partnerID=8YFLogxK

U2 - 10.1021/jm500694p

DO - 10.1021/jm500694p

M3 - Article

C2 - 25079952

AN - SCOPUS:84906862150

VL - 57

SP - 7016

EP - 7030

JO - Journal of Medicinal Chemistry

JF - Journal of Medicinal Chemistry

SN - 0022-2623

IS - 16

ER -